The PERT Consortium™ is pleased to be partnering with AngioDynamics, Inc. on the APEX-AV (Acute Pulmonary Embolism Extraction Trial with the AlphaVac System) study. APEX-AV is an Investigational Device Exemption study that supports a proposed indication for the AlphaVac F1885 PE System in the treatment of Pulmonary Embolism (PE). The APEX-AV trial will enroll up to 122 patients with confirmed acute, intermediate-risk PE at up to 20 sites in the United States.

“On behalf of The National PERT Consortium™, we are incredibly excited to partner with AngioDynamics on the APEX-AV study. The ability to generate high level data on treatments for pulmonary embolism is of utmost importance to our member institutions and our patients, and we are certain APEX-AV will add to a growing body of knowledge in this space.”

– Brent Keeling, MD, President, The PERT Consortium™